Ortin Global Limited share price
Ortin Global Limited engages in the manufacture and trading of pharmaceuticals, drugs, and intermediates in India. The company offers various pharmaceutical formulations of tablets, capsules, syrups, and dry powders; formulations, such as anti-diabetics, anti-allergics, anti-anginal and cardiovascular, sedatives and tranquilisers, anti-helmenthetics, analgesics and antipyretics, anti-biotics-quinolones, anti-biotic-pencillins, antifungal, cephalosporins, and macrolides. Its formulations also include chemo therapeutics, antacids and anti-ulcerants, anti-spasmodics, calcium and iron preparations, anti-arthritic drugs, protein supplements, enzymes, and vitamins, as well as psychiatry, appetize…Read more
- Market Cap₹ 12 Cr.
- Current Price₹ 14.34
- High / Low₹ 21 / 11
- Stock P/E—
- Book Value₹ 1
- Dividend Yield0.00 %
- ROCE-32.2 %
- ROE-46.10 %
- Face Value₹ 10.0
More figures (10)
- EPS (TTM)₹ -1.12
- Price / Book10.78
- OPM-1,030.5 %
- Debt / Equity0.81
- Sales growth (5Y)-58.5 %
- Profit growth (5Y)—
- Promoter holding20.5 %
- EV / EBITDA-9.9
- Beta0.49
- All-time high₹ 52
Price chart
| Returns | 1M | 3M | 6M | YTD | 1Y | 3Y CAGR | 5Y CAGR |
|---|---|---|---|---|---|---|---|
| ORTINGLOBE | -16.87% | -8.89% | -5.97% | +3.84% | +19.70% | -10.86% | -14.47% |
| Nifty 50 | -0.31% | -3.85% | -4.34% | -11.42% | -9.53% | +5.46% | +4.76% |
Price returns only (dividends not included). Prices from NSE via Yahoo Finance; may be delayed.
Quick take
- Ortin Global Limited is in the Drug Manufacturers - Specialty & Generic industry (Healthcare), with a market value of ₹12 crore.
- Revenue grew -58.5% a year over the last 5 years.
- Return on equity was -46.1% and return on capital employed -32.2% in the latest year.
- Debt was 0.81 times shareholders' equity.
- The share price is 32.7% below its 52-week high and up 19.7% over one year.
- Promoters and insiders hold about 20.5%; institutions about 0.0%.
Pros
AINo standout strengths in the reported figures.
Cons
AI- Return on equity has been low: -66.3% on average over the last 3 years.
- Interest cover is thin: operating earnings are -496.3 times the interest cost.
- Sales growth has been slow: -58.5% a year over the last 5 years.
- Promoter holding has fallen by 6.12 points over 3 years, to 1.24%.
- Trades at 10.8 times its book value.
Pros and cons are generated automatically from the reported figures. They are observations, not a recommendation to buy or sell.
AI analysis
Plenitude AI reads the figures on this page and explains them in plain language. It does not say whether to buy or sell.
About Ortin Global Limited
Ortin Global Limited engages in the manufacture and trading of pharmaceuticals, drugs, and intermediates in India. The company offers various pharmaceutical formulations of tablets, capsules, syrups, and dry powders; formulations, such as anti-diabetics, anti-allergics, anti-anginal and cardiovascular, sedatives and tranquilisers, anti-helmenthetics, analgesics and antipyretics, anti-biotics-quinolones, anti-biotic-pencillins, antifungal, cephalosporins, and macrolides. Its formulations also include chemo therapeutics, antacids and anti-ulcerants, anti-spasmodics, calcium and iron preparations, anti-arthritic drugs, protein supplements, enzymes, and vitamins, as well as psychiatry, appetizer, gynaec, and anti-retroviral products. In addition, the company offers active pharmaceutical ingredient (API) intermediates, including anti-retroviral, anti-diabetics, analgesics and antipyretics, a…
- Employees
- 8
- Head office
- Hyderabad
Peer comparison
HealthcareDrug Manufacturers - Specialty & Generic
| S.No. | Company | CMP ₹ | P/E | Mar Cap ₹ Cr | Div Yld % | NP Qtr ₹ Cr | Qtr Profit Var % | Sales Qtr ₹ Cr | Qtr Sales Var % | ROCE % | ROE % | P/B | OPM % | Debt / Eq | Prom. Hold. % | Sales ₹ Cr | Sales Var 3Yrs % |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1. | Ortin Global | 14.34 | — | 12 | 0.00 | -0 | — | 0 | -70.85 | -32.2 | -46.1 | 10.78 | -1,030.5 | 0.81 | 20.46 | 0 | -58.5 |
| 2. | Sun Pharmaceutical Industries | 1,758.80 | 34.9 | 4,21,995 | 0.91 | 2,895 | 34.65 | 15,184 | 18.48 | 17.9 | 14.7 | 5.05 | 23.4 | 0.06 | 55.61 | 58,220 | 10.4 |
| 3. | Divi's Laboratories | 9,144.50 | 83.0 | 2,42,758 | 0.33 | 902 | 36.25 | 3,080 | 19.15 | 19.0 | 16.2 | 14.48 | 28.4 | 0.00 | 52.00 | 10,476 | 11.0 |
| 4. | Torrent Pharmaceuticals | 4,558.90 | 72.8 | 1,73,406 | 0.83 | 566 | 3.28 | 4,835 | 54.57 | 9.1 | 27.1 | 18.39 | 25.0 | 1.79 | 63.18 | 13,753 | 13.3 |
| 5. | Zydus Lifesciences | 1,123.00 | 25.0 | 1,12,020 | 0.09 | 940 | -19.74 | 7,802 | 24.03 | 19.0 | 19.7 | 4.17 | 21.7 | 0.46 | 75.18 | 26,720 | 16.5 |
| 6. | Laurus Labs | 2,060.10 | 101.8 | 1,11,310 | 0.12 | 362 | 123.94 | 2,026 | 29.10 | 19.5 | 18.2 | 20.98 | 19.4 | 0.48 | 32.03 | 6,813 | 3.8 |
| 7. | Cipla | 1,325.10 | 31.8 | 1,07,051 | 0.98 | 789 | -35.42 | 7,077 | 7.26 | 14.9 | 11.8 | 3.11 | 17.5 | 0.02 | 31.13 | 27,712 | 7.2 |
| 8. | Dr. Reddy's Laboratories | 1,233.00 | 31.0 | 1,02,707 | 0.66 | 444 | -68.72 | 8,071 | -5.56 | 14.2 | 12.1 | 2.68 | 14.9 | 0.21 | 30.14 | 33,593 | 11.0 |
| 9. | Aurobindo Pharma | 1,666.90 | 26.0 | 95,910 | 0.00 | 1,033 | 14.29 | 9,106 | 8.65 | 13.5 | 9.9 | 2.56 | 15.6 | 0.21 | 54.79 | 33,385 | 10.7 |
| 10. | Mankind Pharma | 2,275.50 | 46.0 | 93,988 | 0.00 | 568 | 35.00 | 4,031 | 30.89 | 13.7 | 12.5 | 5.76 | 19.9 | 0.39 | 75.39 | 14,278 | 17.7 |
| Median: 34 Co. | 1,712.85 | 34.1 | 33,152 | 0.34 | 679 | 14.29 | 5,956 | 18.81 | 14.6 | 16.9 | 4.96 | 17.9 | 0.30 | 53.40 | 20,499 | 13.5 |
Companies in the same industry; the median covers every company in it that we hold figures for. Tap a heading to sort. Sorting and comparing are ways to explore data, not recommendations.
Quarterly Results
Standalone figures in ₹ crore
Source: the company's results filed with NSE, as reported. Tap a row marked + for its breakdown. Latest quarter on the right.
Profit & Loss
Standalone figures in ₹ crore
Projection — your assumptions
Starts from the last four reported quarters (TTM) and applies the figures you enter; growth is pre-filled with the company's own 3-year sales growth. This is a what-if calculator for illustration, not a forecast, estimate or recommendation.
Related party transactions
Related-party transactions are dealings with promoters, directors, subsidiaries and associates. Companies disclose them to the exchanges every half-year and in detail in the notes to their annual report.
- Related Party TransactionsOrtin Laboratories Limited has informed the Exchange about related Party Transactions30-May-2023
- Related Party TransactionOrtin Laboratories Limited has informed the Exchange about related party transaction for the period ended September 202228-Nov-2022
- Related Party TransactionOrtin Laboratories Limited has informed the Exchange about related party transaction for the period ended March 202213-Jun-2022
- Related Party TransactionsOrtin Laboratories Limited has informed the Exchange about related Party Transactions22-Nov-2021
- Related Party TransactionsOrtin Laboratories Limited has informed the Exchange about related Party Transactions29-Jul-2021
Full details: notes to the Financial Year 2026 annual report (related party disclosures).
| ₹ Cr | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|
| 8 | 8 | 6 | 2 | 0 | 0 | 0 | |
| YOY Sales Growth % | 0.78% | -26.86% | -64.93% | -83.79% | -70.63% | ||
| 7 | 8 | 5 | 9 | 1 | 1 | 1 | |
| Material Cost % | 48% | 57% | 56% | 176% | 63% | 96% | 83% |
| Employee Cost % | 13% | 12% | 14% | 27% | 45% | 155% | 221% |
| Other Expenses % | 24% | 27% | 21% | 207% | 251% | 880% | 1,414% |
| Operating Profit | 1 | 0 | 1 | -7 | -1 | -1 | -1 |
| OPM % | 15% | 5% | 9% | -310% | -258% | -1,030% | -1,619% |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Exceptional items | -0 | 0 | |||||
| Interest | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | 0 | -1 | -0 | -7 | -1 | -1 | -1 |
| -593% | |||||||
| Current tax | 0 | 1 | |||||
| Deferred tax | -1 | -0 | -0 | -0 | 0 | 0 | |
| 1 | -0 | -0 | -8 | -1 | -1 | -1 | |
| YOY Profit Growth % | -142.18% | ||||||
| EPS in Rs | 1.16 | -0.49 | -0.08 | -9.89 | -1.04 | -0.91 | -1.12 |
Compounded Sales Growth
- 5 Years:
- -59%
- 3 Years:
- -74%
- TTM:
- -58%
Stock Price CAGR
- 5 Years:
- -14%
- 3 Years:
- -11%
- 1 Year:
- 20%
Return on Equity
- 4 Years:
- -50%
- Last Year:
- -46%
Financial years ending March; TTM = the last four quarters. Source: the company's results filed with NSE, as reported. Tap a row marked + for its breakdown. Dividend payout = dividends paid in the year ÷ net profit.
Balance Sheet
Consolidated figures in ₹ crore, as at 31 March
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Equity Capital | 8 | 8 | 8 | 8 |
| Reserves | 3 | -5 | -6 | -7 |
| 6 | 2 | 0 | 1 | |
| Long term borrowings | 3 | 2 | 0 | 1 |
| Short term borrowings | 3 | 0 | ||
| 4 | 2 | 2 | 2 | |
| Trade payables | 2 | 0 | 0 | 0 |
| Current liabilities | 7 | 2 | 2 | 2 |
| Total Liabilities | 21 | 7 | 4 | 5 |
| 14 | 0 | 0 | 0 | |
| Gross block | 19 | 0 | 0 | 0 |
| Accumulated depreciation | 5 | 0 | 0 | 0 |
| CWIP | 0 | |||
| 6 | 7 | 4 | 5 | |
| Inventories | 3 | 0 | 0 | |
| Trade receivables | 3 | 2 | 0 | 0 |
| Cash & equivalents | 0 | 0 | 0 | 1 |
| Current assets | 7 | 6 | 3 | 4 |
| Total Assets | 21 | 7 | 4 | 5 |
Source: Yahoo Finance (compiled from the annual reports). Tap a row marked + for its breakdown.
Cash Flows
Consolidated figures in ₹ crore, financial years ending March
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| -0 | -5 | -0 | -1 | |
| Profit for the year | -0 | -8 | -1 | -1 |
| Working capital changes | -1 | 1 | 0 | 0 |
| Direct taxes paid | -1 | |||
| 0 | 12 | -0 | 0 | |
| Fixed assets purchased | -0 | -0 | ||
| Fixed assets sold | 12 | 0 | ||
| 1 | -3 | 0 | 1 | |
| Interest paid | -0 | -0 | -0 | -0 |
| Net Cash Flow | 1 | 4 | -0 | 0 |
| Free Cash Flow | -0 | -5 | -0 | -1 |
Free cash flow = cash from operations − capital expenditure. Source: Yahoo Finance.
Ratios
| Ratio | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| ROE | — | -0.9% | -117.5% | -35.3% | -46.1% |
| ROCE | — | 1.7% | -142.9% | -37.5% | -32.2% |
| Operating margin | — | 4.5% | -211.7% | -261.6% | -1,030.5% |
| Net margin | — | -1.6% | -380.8% | -247.3% | -736.7% |
| Debt / equity | — | 0.59 | 0.64 | 0.13 | 0.81 |
| Current ratio | — | 0.94 | 3.11 | 2.15 | 1.60 |
| Debtor days | — | 207 | 305 | 279 | 728 |
| Inventory days | — | 280 | 5 | 34 | 0 |
| Days payable | — | 167 | 8 | 72 | 145 |
| Cash conversion cycle | — | 320 | 302 | 241 | 583 |
| Working capital days | — | -27 | 744 | 1,908 | 5,202 |
Computed from the reported statements: ROE on average equity; ROCE = EBIT / (total assets − current liabilities). Debtor days = receivables ÷ sales × 365; inventory and payable days use cost of goods sold; cash conversion cycle = debtor + inventory − payable days; working capital days = (current assets − current liabilities) ÷ sales × 365.
Shareholding Pattern
Numbers in percentages · as filed with NSE each quarter
- Promoters 1.24%
- FIIs 0.67%
- Public 98.09%
| % | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 7.36% | 1.23% | 1.23% | 1.23% | 1.23% | 1.23% | 1.23% | 1.23% | 1.23% | 1.23% | 1.23% | 1.24% |
| 6.25% | 6.25% | 6.25% | 6.53% | 6.53% | 1.68% | 1.68% | 1.68% | 1.80% | 0.67% | |||
| Foreign portfolio investors (Cat. I) | 6.25% | 6.25% | 6.25% | 6.53% | 6.53% | 1.68% | 1.68% | 1.68% | 1.80% | 0.67% | ||
| 92.64% | 98.77% | 92.52% | 92.52% | 92.52% | 92.24% | 92.24% | 97.09% | 97.09% | 97.09% | 96.96% | 98.09% | |
| Retail (up to ₹2 lakh) | 63.62% | 63.92% | 60.71% | 61.08% | 61.23% | 62.24% | 61.70% | 60.66% | 58.38% | 54.19% | 54.45% | 55.03% |
| HNIs (above ₹2 lakh) | 22.44% | 28.11% | 25.13% | 22.47% | 23.03% | 23.08% | 23.96% | 30.19% | 32.63% | 37.00% | 36.41% | 36.10% |
| NRIs | 1.06% | 1.05% | 1.08% | 1.07% | 1.14% | 1.26% | 1.23% | 1.10% | 1.09% | 0.94% | 2.17% | 2.51% |
| Bodies corporate | 3.60% | 3.61% | 3.20% | 5.61% | 4.91% | 3.37% | 3.06% | 2.89% | 2.94% | 3.02% | 2.18% | 2.58% |
| No. of Shareholders | 12,314 | 12,192 | 11,952 | 12,165 | 12,094 | 12,144 | 12,034 | 12,060 | 11,834 | 11,452 | 11,383 | 11,151 |
Source: shareholding patterns filed by the company with NSE. Public = non-institutional holders. Tap a row marked + for its breakdown.
Documents
Announcements
- Certificate under SEBI (Depositories and Participants) Regulations, 2018ORTIN GLOBAL LIMITED has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 201810-Oct-2026
- Shareholders meetingORTIN GLOBAL LIMITED has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on September 30, 2026. Further, the company has informed the Exchange rega…01-Oct-2026
- Shareholders meetingORTIN GLOBAL LIMITED has informed the Exchange regarding Proceedings of Annual General Meeting held on September 30, 202630-Sep-2026
- Trading WindowORTIN GLOBAL LIMITED has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 201522-Sep-2026
- Resignation of Director/KMP/SMPORTIN GLOBAL LIMITED has informed the Exchange about Resignation of Director/KMP/SMP08-Sep-2026
- Shareholders meetingORTIN GLOBAL LIMITED has informed the Exchange regarding Notice of Annual General Meeting to be held on September 30, 202608-Sep-2026
- Change in Director(s)ORTIN GLOBAL LIMITED has informed the Exchange regarding Change in Director(s) of the company.07-Sep-2026
- Outcome of Board MeetingORTIN GLOBAL LIMITED has informed the Exchange regarding Outcome of Board Meeting held on September 07, 2026.07-Sep-2026
- Outcome of Board MeetingORTIN GLOBAL LIMITED has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.14-Aug-2026
- UpdatesRarever Financial Advisors Private Limited has submitted to the Exchange a copy of Post-offer advertisement under Regulation 18(12) in terms of the SEBI (SAST) Regulations, 201…13-Jul-2026
- Certificate under SEBI (Depositories and Participants) Regulations, 2018ORTIN GLOBAL LIMITED has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 201811-Jul-2026
- Reply to Clarification- Financial resultsThe Exchange had sought clarification from ORTIN GLOBAL LIMITED for the quarter ended 31-Mar-2026 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Req…09-Jul-2026
Annual reports
- Financial Year 202608-SEP-2026
- Financial Year 202508-SEP-2025
- Financial Year 202407-SEP-2024
- Financial Year 2023
- Financial Year 2022
- Financial Year 2021
Credit ratings
None filed recently.
Concalls & investor meets
None filed recently.
Filings made by the company with NSE; documents open on NSE's website.
Key dates
- Ex-dividend date
- 1 Jan 1970
- Latest quarter
- 30 Jun 2026
- Financial year end
- 31 Mar 2026
Trade with our broking desk
Open a trading & demat account through Parshvanath Investments, Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539; NSE AP0153037862, BSE AP01095201177059). Execution and service only: no tips or research.
Latest news
From the company (NSE)
- Certificate under SEBI (Depositories and Participants) Regulations, 2018ORTIN GLOBAL LIMITED has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018NSE filing · 10-Oct-2026
- Shareholders meetingORTIN GLOBAL LIMITED has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on September 30, 2026. Further, the company has informed the Exchange rega…NSE filing · 01-Oct-2026
- Shareholders meetingORTIN GLOBAL LIMITED has informed the Exchange regarding Proceedings of Annual General Meeting held on September 30, 2026NSE filing · 30-Sep-2026
- Trading WindowORTIN GLOBAL LIMITED has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015NSE filing · 22-Sep-2026
- Resignation of Director/KMP/SMPORTIN GLOBAL LIMITED has informed the Exchange about Resignation of Director/KMP/SMPNSE filing · 08-Sep-2026
- Shareholders meetingORTIN GLOBAL LIMITED has informed the Exchange regarding Notice of Annual General Meeting to be held on September 30, 2026NSE filing · 08-Sep-2026
- Change in Director(s)ORTIN GLOBAL LIMITED has informed the Exchange regarding Change in Director(s) of the company.NSE filing · 07-Sep-2026
- Outcome of Board MeetingORTIN GLOBAL LIMITED has informed the Exchange regarding Outcome of Board Meeting held on September 07, 2026.NSE filing · 07-Sep-2026
Headlines from news publishers (via Google News) and the filings of the company with NSE; they open on the source website. Headlines with price targets or buy/sell calls are left out. News is for information only and is not a recommendation.
Questions about Ortin Global Limited
What is the share price of Ortin Global Limited today?
What is the market cap of Ortin Global Limited?
What is the P/E ratio of Ortin Global Limited?
Is Ortin Global Limited a good investment?
How can I buy Ortin Global Limited shares?
Have a question about this topic?
Tell us a little about your situation and an expert will call you back, usually within 2 hours on business days.
Book your free wealth consultation
- 100% free
- No obligation
- Reply within 2 hours
Request received!
Thank you for trusting Plenitude Connect. An expert will contact you shortly. Please check your inbox for details.